Viral nucleic acids often trigger an innate immune response in infected cells. Many viruses, including hepatitis C virus (HCV), have evolved mechanisms to evade intracellular recognition. Nevertheless, HCV-permissive cells can trigger a viral RNA-, TLR7-, and cell-contact-dependent compensatory interferon response in nonpermissive plasmacytoid dendritic cells (pDCs). Here we report that these events are mediated by transfer of HCV-RNA-containing exosomes from infected cells to pDCs. The exosomal viral RNA transfer is dependent on the endosomal sorting complex required for transport (ESCRT) machinery and on Annexin A2, an RNAbinding protein involved in membrane vesicle trafficking, and is suppressed by exosome release inhibitors. Further, purified concentrated HCV-RNAcontaining exosomes are sufficient to activate pDCs. Thus, vesicular sequestration and exosomal export of viral RNA may serve both as a viral strategy to evade pathogen sensing within infected cells and as a host strategy to induce an unopposed innate response in replication-nonpermissive bystander cells.
INTRODUCTION
Upon sensing invading viruses, host cells trigger signaling events that ultimately lead to the secretion of type I interferons (IFNs) and to the expression of an array of IFN-stimulated genes (ISGs) (Kawai and Akira, 2009) . ISGs are important effectors that suppress viral spread by blocking the viral life cycle at multiple levels (Sadler and Williams, 2008) . Specific motifs known as pathogen-associated molecular patterns (PAMPs), which include viral nucleic acids, are recognized by pattern recognition receptors (PRRs) that mobilize the innate immune response (Kawai and Akira, 2009 ). These receptors can be cytoplasmic (e.g., retinoic inducible gene-I (RIG-I)-like receptors (RLRs) (Kawai and Akira, 2009; Loo and Gale, 2011) and NODlike receptors (Kawai and Akira, 2009) or endosomal (e.g., Toll-like receptors [TLRs] [Blasius and Beutler, 2010; Kawai and Akira, 2011] ). Thus, the current concept of virus-induced innate immune signaling is that recognition of viral nucleic acids typically occurs within cells that are either productively infected or have internalized viral particles (Blasius and Beutler, 2010; Loo and Gale, 2011) .
Many viruses deploy mechanisms designed to avert, subvert, or evade pathogen-sensing pathway (Versteeg and García-Sastre, 2010) . For example, the hepatitis C virus (HCV) has evolved a potent strategy that precludes type 1 IFN induction by infected hepatocytes Liang et al., 2008) . Specifically, the NS3-4A protease of HCV inactivates MAVS/ IPS-1/cardif, the signaling adaptor of the RLR sensing pathway, by proteolytic cleavage (Foy et al., 2005; Horner et al., 2011; Li et al., 2005b; Loo et al., 2006; Meylan et al., 2005) . Furthermore, cleavage of the TIR-domain-containing adaptor-inducing IFN-b (TRIF) adaptor by NS3-4A abrogates signaling transduction induced by endosomal TLR3 (Li et al., 2005a; Wang et al., 2009 ). However, despite these inhibitory mechanisms, HCV infection strongly triggers the expression of ISGs in the liver of experimentally HCV-infected chimpanzees (Bigger et al., 2001 (Bigger et al., , 2004 Su et al., 2002) and naturally HCV-infected humans (Alter and Seeff, 2000) . Therefore, these results suggest the existence of alternative pathogen-sensing mechanisms that are not opposed by viral evasion mechanisms.
In previous studies, we (Takahashi et al., 2010) and others (Dental et al., 2012; Zhang et al., 2012) recently reported that HCV-infected cells trigger plasmacytoid dendritic cells (pDCs) to produce type 1 IFN. We found that pDC-activation occurs in a cell-cell-contact-and TLR7-dependent manner that is dependent on the intracellular HCV-RNA level of cocultured infected cells (Takahashi et al., 2010) . In addition, we showed that induction of the IFN response by pDCs is independent of virus production because HCV subgenomic replicon (SGR) cells that replicate the viral RNA but cannot produce infectious virus particles can also trigger pDCs to produce type 1 IFN (Takahashi et al., 2010) .
Many cell types release membrane-enclosed microvesicles into the extracellular milieu, the best-characterized of which are 40-100 nm endosome-derived secreted vesicles (exosomes; Thé ry et al., 2009 ) that have been shown to transfer functional microRNA and messenger RNA (mRNA) to recipient cells (Kosaka et al., 2010; Meckes et al., 2010; Pegtel et al., 2010; Skog et al., 2008; Valadi et al., 2007) . Based on previous reports showing that the supernatant of HCV-SGR cells contains subgenomic viral RNA (Pietschmann et al., 2002) , that exosome-like structures are present in the supernatant of HCV-infected cells , and that HCV-RNA-containing exosomes are detected in the plasma of HCV-infected patients (Masciopinto et al., 2004) , we reasoned that HCV RNA might be secreted within exosomal vesicles from HCV-infected cells and trigger IFN-a production by pDCs.
Here we report that exosomes are a previously unrecognized PAMP carrier that can mediate cell-to-cell transfer of immunostimulatory viral RNA from infected cells to cocultured pDCs and trigger the production of type 1 IFN. In addition, we define the cellular mechanisms responsible for biogenesis of the PAMPcontaining exosomes. These results demonstrate a previously unsuspected aspect of the innate host response in which infected cells, whose pathogen-sensing machinery is inhibited by viral proteins, utilize exosomes to transfer viral RNA to neighboring noninfectible cells that are specifically designed to respond to viral RNA.
RESULTS
Exosomal Transfer of Viral RNA from HCV-Infected and HCV-SGR Cells to pDCs Triggers IFN-a Production HCV-infected Huh-7.5.1c2 (Pedersen et al., 2007) cells were cocultivated with primary human, peripheral blood-derived pDCs in the presence or absence of two structurally unrelated neutral sphingomyelinase inhibitors (GW4869 and spiroepoxide) that are well-known inhibitors of exosome release (Chairoungdua et al., 2010; Kogure et al., 2011; Kosaka et al., 2010 Kosaka et al., , 2012 Trajkovic et al., 2008; Yuyama et al., 2012) . Both GW4869 and spiroepoxide completely abolished (>2 log reduction) IFN-a secretion by the pDCs ( Figure 1A ) without reducing the intracellular HCV-RNA content of the infected cells ( Figure 1B ) and with little (<5-fold) or no reduction of infectious HCV particle production ( Figure 1C ). Similar results were also obtained using Huh-7.5.1 cells and parental Huh-7 cells (Figures S1A-S1C available online). Remarkably, both compounds also abrogated IFN-a production by pDCs cocultured with HCV-SGR cells (Figure 1D) in a dose-dependent manner ( Figure S1D ) that correlated with the magnitude of inhibition of exosome production (Figure S1F) and exosomal HCV-RNA ( Figure S1G ) release. Neither compound inhibited HCV-RNA replication in the SGR cells ( Figures 1E and S1E ), nor did they inhibit pDC IFN-a production that was triggered by R848 (a specific TLR7 agonist; Kawai and Akira, 2009; Figures 1F and S1D) , thus ruling out potential nonspecific effects of these compounds on pDCs.
The SGR cell results indicated that the pDC immunostimulatory signal could be transmitted via a virus particle-independent pathway. To corroborate this assumption and to determine whether HCV RNA is transmitted to cocultured pDCs even in the absence of virus production, we used a highly sensitive HCV-RNA-specific fluorescence in situ hybridization (FISH) assay to monitor the presence of HCV RNA in infected cells, SGR cells, and cocultivated pDCs. As expected, the intensity of the HCV-RNA signal was much stronger in infected cells (Figure 2A, left panel) than in SGR cells ( Figure 2B , left panel), reflecting the former's $10-fold greater content of HCV RNA (data not shown). Nonetheless, HCV RNA (green) was readily detected in pDCs after 20 hr of cocultivation with HCV-SGR cells ( Figure 2C , middle panel). Combined HCV-RNA FISH and IFN-a immunostaining revealed that HCV RNA was detected in 45.5% (10/22) of IFN-a-positive pDCs and 8.6% (9/105) IFN-a-negative pDCs after cocultivation with SGR cells ( Figure 2D ) but was never detectable (0/61) in pDCs cocultured with HCV-negative cells (not shown). Collectively, these results suggest that both HCVinfected cells and SGR cells release HCV-RNA-containing exosomes that transfer HCV RNA to cocultured pDCs and trigger IFN-a production. The exosomal nature of the transfer process is underscored by the transfer of HCV RNA to pDCs by SGR cells in which virus particle production cannot occur.
HCV RNA Is Selectively Packaged within Exosomes that Trigger pDC IFN-a Production Exosomes are endosome-derived secreted vesicles (Thé ry et al., 2009 ) that are formed by membrane invagination within multivesicular bodies (MVBs) and exocytosed by fusion of the MVB membrane with the cell surface membrane (Bobrie et al., 2011; Thé ry et al., 2009 ). HCV-RNA-containing exosomes cannot be readily distinguished or physically separated from infectious HCV particles by conventional biophysical techniques because they share similar buoyant densities and sedimentation velocities (Lindenbach et al., 2005; Meckes and Raab-Traub, 2011) ; therefore, we used HCV-SGR cells in all subsequent studies to analyze the exosome-mediated transfer process without the potentially confounding impact of coexisting virus particles. We view the results of these SGR-cell-based studies as being representative of HCV-infected cells because both infected and SGR cells trigger IFN-a production by pDCs in a TLR-7dependent and cell-cell-contact-dependent manner (Takahashi et al., 2010) that in both cases is antagonized by exosome release inhibitors ( Figure 1 ).
First, we asked whether there was evidence that HCV RNA might colocalize in HCV-SGR cells with proteins that are known to be enriched in exosomes (e.g., CD63, CD81, and CHMP4B; Bobrie et al., 2011; Thé ry et al., 2009) . As shown in Figure 3 , HCV RNA colocalized with a subset of CD63-, CD81-, and CHMP4B-positive signals in HCV-SGR cells, consistent with the notion that HCV RNA could be incorporated into intracellular vesicles destined to become exosomes.
Next, we asked whether membrane-bound HCV RNA is released into the supernatant of HCV-SGR cells that do not produce HCV structural proteins and thus cannot produce virus particles. As shown in Figures 4A-4C , the supernatant of HCV-SGR cells contained >10 6 copies per milliliter of HCV RNA that was resistant to digestion by ribonuclease A (RNase) unless it was also exposed to NP40. These results suggested that the secreted HCV RNA was contained within lipid membrane-bound vesicles. Additionally, we showed that the extracellular HCV RNA was not merely present in cellular debris, since it was >100-fold more abundant than the extracellular glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA content in the same supernatants ( Figure 4D ), whereas the intracellular HCV-RNA content was less abundant than GAPDH mRNA in the corresponding SGR cells ( Figure 4D ).
Finally, exosomes were prepared from the supernatants of HCV-SGR cells and analyzed for their protein and RNA content and their ability to trigger IFN-a production by pDCs. As shown in Figures 5A, S1F, and S2A, the concentrated exosome preparations were specifically enriched in the exosome markers CD63 and CD81 relative to nonexosomal cellular proteins EEA1 (an endosome marker), calnexin (an ER marker), COX IV (a mitochondrial marker), and ARF1 (a Golgi marker). Importantly, the concentrated exosome preparations contained >10 5 copies of HCV RNA (per microgram of total protein) that were >150-fold concentrated relative to the amount of HCV RNA in the corresponding unconcentrated SGR-cell supernatants (i.e., approximately 4-8 3 10 8 versus 2-4 3 10 6 GE/ml, respectively; Figures S1G and 4A, respectively), >100-fold enriched relative to GAPDH mRNA ( Figure 5B ), and fully protected from RNase digestion unless they were also treated with NP40 ( Figure 5B ). Interest-ingly, northern blot analysis of the exosome-associated RNA revealed that the HCV RNA comigrated with the dominant HCV-RNA species present in the corresponding HCV-SGR cells ( Figure 5C ), suggesting that it represented a full-length HCV-SGR genome (i.e., 8,024 nucleotides). Importantly, the viral NS4B and NS5A proteins and calnexin, all of which are known to be present in HCV replication complexes (Backes et al., 2010; El-Hage and Luo, 2003) , were not detected in concentrated exosome preparations ( Figure S2A ). Collectively, these results suggest that the RNase-resistant extracellular HCV RNA reflects the release of viral RNA-containing exosomes from SGR cells rather than HCV replication complexes that, theoretically, could be present in cellular debris in the (A-C) Quantification of IFN-a in supernatants of pDCs cocultured with HCV-infected Huh-7.5.1c2 cells (moi of 1 for 48 hr) that were treated or not with exosomerelease inhibitors GW4869 or spiroepoxide (10 and 5 mM, respectively) throughout the course of the coculture (A). Uninfected Huh-7.5.1c2 cells are referred to as control (cont) cells. The hatch marks (#) indicate results below the limit of detection of the IFN-a ELISA (i.e., 12.5 pg/ml). In parallel, the intracellular HCV-RNA levels (B) and extracellular infectious virus production (C) of HCV-infected cells treated with exosome release inhibitors were analyzed. Results are representative of two independent experiments, each performed in triplicate. Error bars represent the mean ± SD. (D) Quantification of IFN-a in supernatants of pDCs cocultured with HCV-SGR Huh-7.5.1c2 cells after treatment with exosome-release inhibitors GW4869 or spiroepoxide (treatment with 10 and 5 mM, respectively) throughout the course of the coculture. HCV-negative Huh-7.5.1c2 cells served as controls (cont cells).
(E) Intracellular HCV-RNA levels in HCV-SGR cells treated for 24 hr with exosome release inhibitors. (F) Parallel pDC/control cell cocultures were incubated with the TLR-7 ligand agonist R848 and supernatants were analyzed for IFN-a. Results in (D)-(F) are representative of three independent experiments, each performed in triplicate. Bar graphs depict the mean ± SD. The treatment conditions (i.e., incubation time and concentration) were exactly the same for the analysis of IFN-a production, HCV-RNA replication, and extracellular infectious virus production. See also Figure S1 . culture supernatants. Additionally, as shown in Figure S2B , buoyant density separation analysis revealed that the extracellular HCV RNA cofractionated with exosome markers (CD81 and CD63) and displayed the expected density profile of exosomes (1.10-1.19 g/ml; Meckes and Raab-Traub, 2011) rather than HCV replicase complexes (>1.17 g/ml; Ferraris et al., 2010; Villanueva et al., 2010) or apoptotic bodies (1.24-1.28 g/ml; Meckes and Raab-Traub, 2011) . Importantly, highly concentrated exosomes prepared from HCV-SGR cells triggered IFN-a production by pDCs in a dose-dependent manner ( Figure 5D ). Collectively, these results suggest that HCV RNA is selectively packaged in exosomes that transfer it to pDCs that respond by secreting IFN-a.
Nuclei
ESCRT Proteins Are Required for HCV-Infected and HCV-SGR Cells to Trigger pDC IFN-a Production The endosomal sorting complex required for transport (ESCRT) machinery is known to be required for exosome biogenesis (Baietti et al., 2012; Fé vrier and Raposo, 2004; Tamai et al., 2010) . To determine whether it is also required for generation of the pDC-activating signal by HCV-infected Huh-7.5.1c2 cells and SGR cells, we used lentivirus vector-based small hairpin RNA (shRNA) transduction to inhibit the expression of chromatin-modifying protein 4B (CHMP4B; Figure 6A , upper left panel), a component of complex III of the ESCRT machinery (Hurley and Hanson, 2010) . Importantly, the ability of CHMP4Bdownregulated HCV-SGR cells to stimulate IFN-a production by cocultured pDCs was strongly inhibited ( Figure 6A , middle panel, lanes 4 and 5), whereas their ability to support HCV replication was unchanged ( Figure 6A , lower panel, lanes 4 and 5). In contrast, shRNAs that target either an irrelevant (green fluorescent protein [GFP]; Figure 6A , middle panel, lane 3) or an unrelated nonESCRT protein (Atg4B; Figure 6A , middle panel, lane 6) did not impair IFN-a production by cocultured pDCs. To confirm these results, we asked whether tumor susceptibility gene 101 (TSG101) 
Cell Host & Microbe
Exosomes Transfer HCV RNA to pDCs and Trigger IFN of the ESCRT machinery (Hurley and Hanson, 2010) , was required for the HCV-SGR cells to trigger pDC IFN-a production. Again, downregulation of TSG101 expression in HCV-SGR cells ( Figure 6B, upper panel) abolished their ability to trigger pDC IFN-a production ( Figure 6B , middle panel) without inhibiting HCV-RNA replication ( Figure 6B, lower panel) . These results strongly suggest that MVBs play a key role in the production of the pDC-activating signal by SGR cells.
Importantly, we confirmed these results by demonstrating that shRNA-mediated downregulation of CHMP4B and TSG101 expression in HCV-infected cells ( Figure 6C ) either abrogated or markedly impaired (by $60-fold) their ability to trigger pDC IFN-a production ( Figure 6D, upper panel) , and, consistent with previous reports (Ariumi et al., 2011; Corless et al., 2010; Tamai et al., 2012) , had little or no impact on HCV-RNA replication ( Figure 6D, lower panel) , and a modest effect (i.e., <2-to 4-fold reduction) on infectious virus production ( Figure 6E ). Similar results were obtained using Huh-7.5.1 cells and parental Huh-7 cells ( Figure S3 ). Collectively, these results indicate that the ESCRT machinery is required for HCV-infected and SGR cells to activate pDCs, suggesting that MVBs are required for this process and reinforcing the notion that the pDC activating signal is exosomal HCV RNA.
ANXA2 Is Required for HCV-Infected and HCV-SGR Cells to Trigger pDC IFN-a Production Annexin A2 (ANXA2) is an RNA-binding protein (Aukrust et al., 2007; Filipenko et al., 2004) that plays a key role in membrane vesicle trafficking and MVB biogenesis (Gerke et al., 2005; Mayran et al., 2003; Morel et al., 2009) . Interestingly, recent reports indicated that ANXA2 is recruited to HCV replication sites where it regulates virus particle production (Backes et al., 2010; Saxena et al., 2012) . Therefore, we used shRNA-mediated knockdown to determine whether ANXA2 is required for HCVinfected Huh-7.5.1c2 cells and SGR cells to trigger IFN-a production by cocultured pDCs. As shown in Figure 7 , ANXA2 downregulation in HCV-SGR cells ( Figure 7A ) abolished their ability to trigger IFN-a production by cocultured pDCs ( Figure 7B ) without inhibiting HCV-RNA replication ( Figure 7C ), the latter confirming the results of Backes et al. (2010) . The ANXA2 requirement for pDC activation was confirmed by the restoration of pDC activation by ANXA2 shRNA-downregulated SGR cells by ectopic overexpression of an ANXA2 encoding shRNA-resistant RNA ( Figure 7B ). Consistent with these results, downregulation of ANXA2 expression in HCV-infected cells ( Figure 7D ) decreased their ability to trigger IFN-a production by cocultured pDCs by >20-fold ( Figure 7E ) without inhibiting HCV-RNA replication ( Figure 7F ) or significantly (<2.5-fold) suppressing infectious virus production ( Figure 7G ). Similar results were obtained using Huh-7.5.1 cells and parental Huh-7 cells (Figure S4) . Altogether, these results demonstrate that ANXA2 is required for both HCV-SGR cells and HCV-infected cells to trigger IFN-a production by pDCs, possibly by orchestrating the recruitment of appropriate cellular and/or viral components to generate the HCV-RNA-containing exosomes that trigger the pDC IFN response. Reizis et al., 2011) . The pDC response to these stimuli typically occurs when they are infected by viruses such as respiratory syncytial virus, influenza virus, and lymphocytic choriomeningitis infection (Blasius and Beutler, 2010; Hornung et al., 2004; Lee et al., 2007; Loo and Gale, 2011; Macal et al., 2012) , resulting in the rapid secretion of type 1 IFN in a response that is up to 1,000-fold more vigorous than in other similarly infected cell types (Liu, 2005) .
DISCUSSION
In contrast to these conventional mechanisms for pDC activation, here we define a host strategy that ensures recognition of infectious agents that on one hand defeat the pathogen-sensing machinery in the cells they infect, and on the other hand do not productively infect pDCs (Decalf et al., 2007) . Using HCV as a model, we demonstrate that HCV-permissive cells that do not produce type 1 IFN because the HCV NS3/4A protease interrupts the RLR and TLR signaling pathways in the cells Foy et al., 2005; Horner et al., 2011; Li et al., 2005a Li et al., , 2005b Liang et al., 2008; Loo et al., 2006; Meylan et al., 2005; Wang et al., 2009) can selectively package immunostimulatory viral RNA within exosomes that deliver their RNA cargo to neighboring, HCV-nonpermissive (Decalf et al., 2007) pDCs in a concentration-dependent manner that triggers an antiviral IFN response. We suggest that this mechanism may have evolved to protect the host against pathogens that, like HCV, can blunt the IFN response in productively infected cells (Versteeg and García-Sastre, 2010) .
To unambiguously dissect the exosomal transmission of immunostimulatory HCV RNA without the potentially confounding effect of HCV-RNA-containing virus particles, in many experiments we used SGR cells that replicate a subgenomic fragment of viral RNA that encodes only the HCV nonstructural proteins and thus cannot assemble virus particles. The results from those experiments, as well as others performed in HCV-infected cells using exosome release inhibitors and shRNA downregulation of the ESCRT machinery and ANXA2, reveal that immunostimulatory HCV RNA is produced by SGR cells and infected cells, packaged within exosomes, and transferred to cocultured pDCs that it triggers to produce type I IFN. Exosome formation is initiated in MVBs by invagination of endosomal membranes and generation of intraluminal vesicles (ILV; Al-Nedawi et al., 2008; Bobrie et al., 2011; Couzin, 2005; Fé vrier and Raposo, 2004; Lié geois et al., 2006) . Importantly, HCV RNA colocalized with CD63, CD81, and CHMP4B proteins, which are known to be enriched in MVB (Figure 3 ), suggesting that HCV RNA is directed to this cellular compartment by an as yet unknown mechanism. The ESCRT machinery regulates membrane budding and ILV formation at the late endosome level (Henne et al., 2011; Raiborg and Stenmark, 2009) , and ESCRT components are thus involved in exosome biogenesis (Baietti et al., 2012; Fé vrier and Raposo, 2004; Tamai et al., 2010) . Therefore, one might speculate that ESCRT proteins, such as Tsg101 and CHMP4B, may contribute to the processes of membrane bending and abscission that direct HCV RNA to ILVs and exosomes. Alternatively, Tsg101 and CHMP4B may be indirectly involved in endosomal compartments that require ESCRTs for their architectural and functional integrity (Doyotte et al., 2005; Razi and Futter, 2006) .
Although exosomal transfer of functional cellular mRNA and microRNA to recipient cells has been previously reported (Kosaka et al., 2010; Meckes et al., 2010; Pegtel et al., 2010; Skog et al., 2008; Valadi et al., 2007) , to our knowledge, our demonstration that exosomes can mediate the transfer of (C) Northern blot analysis. The input copy number of HCV and GADPH RNA determined by qRT-PCR is indicated below each blot. Huh-7.5.1c2 cells served as negative control (cont cells). NA, not applicable. (D) pDCs (4 3 10 5 cells) were incubated with concentrated exosomes at varying HCV GE/pDC ratios or with R848, a TLR7 agonist. The hatch marks (#) indicate results below the limit of detection of the IFN-a ELISA (12.5 pg/ml). Results are representative of two independent experiments. Error bars represent the mean ± SD. See also Figure S2 . immunostimulatory viral RNA to type I-IFN-producing pDCs in a cell-cell-contact-dependent manner reveals a previously unappreciated aspect of the innate immune response to viral infection. In addition, it is conceivable that exosome-mediated export of viral RNA may have a variety of unexpected and potentially alternative outcomes. For example, it could theoretically enhance viral clearance by purging viral RNA from the cell. Alternatively, it could have proviral effects by vesicular sequestration of otherwise immunostimulatory RNA from the cytosolic RNA sensing machinery of the cell. It is also conceivable that HCV-RNA-containing exosomes might also transfer infectious viral genomes to cells (e.g., hepatocytes) that are permissive for viral replication, in which case it would facilitate cell-to-cell spread of an infection that is unconstrained by a neutralizing antibody response. Additional experiments will be required to test these interesting hypotheses.
We are intrigued by the fact that although pDC activation is exosome mediated, it requires cell-cell contact because unconcentrated supernatants from either infected cells or SGR cells do not trigger IFN-a production by pDCs (Takahashi et al., 2010) . This suggests that HCV-infected cells and SGR cells secrete exosomes into the culture supernatant at concentrations that are below an excitatory threshold that could be reached in the intercellular space during cell-cell contact. This is corroborated by the fact that the maximal HCV/pDC ratio achieved by the coincubation of unconcentrated SGR cell supernatants with pDCs (i.e., $0.2-0.5 HCV genomes/ pDC) is not sufficient to trigger IFN-a production (data not shown; Takahashi et al., 2010) . In contrast, SGR-cell supernatant-derived exosome preparations containing at least 10-fold higher HCV-RNA concentrations (i.e., HCV-RNA/pDC ratio of at least 2) are required to trigger low-level pDC IFN-a production, and at least 45 HCV-RNA copies per pDC are needed for robust pDC activation ( Figure 5D ). Interestingly, whereas HCV RNA was detectable by FISH in only $10%-15% of total pDC, it was detectable in three times as many IFN-a-positive pDCs ( Figure 2D ). The absence of HCV RNA in many IFNa-positive pDCs may imply that they were stimulated in a paracrine fashion by IFN-a, as previously suggested (Takahashi et al., 2010) . Importantly, the detection of HCV RNA in 8.6% of IFN-a-negative pDCs may suggest that either independent subsets of pDCs are differentially responsive to the HCV-RNA stimulus, or that a certain amount of time is needed so that HCV RNA can trigger pDCs to produce enough IFN-a to be detectable, and the pDCs were observed before that threshold was reached.
The potential physiological relevance of the process described in this report is supported by the facts that exosome-mediated cell-cell transmission of siRNA occurs between hepatocytes in vivo (Pan et al., 2012) , that HCV-RNA-containing exosomes are detectable in the plasma of chronically HCVinfected patients (Masciopinto et al., 2004) , that pDCs are abundant in HCV-infected liver (Lau et al., 2008) , and that pDCs from HCV-infected patients respond normally to HCV-infected cells (Takahashi et al., 2010) . Therefore, at least theoretically, pDC IFN production triggered by exosomes released by neighboring HCV-infected hepatocytes could occur during natural HCV infection. Additional experiments will be necessary to formally test this hypothesis.
In summary, the current results illustrate a previously unsuspected aspect of the innate host response in which the vesicular transport machinery in a virus-infected cell produces immunostimulatory viral RNA-containing exosomes that are transferred at close range to professional IFN-producing cells whose ability to trigger an innate response is not opposed because they are not permissive for infection. These results may have broad implications for our understanding of the host-virus relationship, because cell-cell-contact-dependent and TLR7-dependent pDC activation is now known to extend to cells that replicate alphaviruses (Takahashi et al., 2010) , to HIV infection (Lepelley et al., 2011) , and to a wide variety of human (e.g., Huh-7 and HeLa) and animal (e.g., NIH 3T3) cells that are infected by lymphocytic choriomeningitis virus (S.W., K. Takahashi, B.B., U.G., J.C. de la Torre, and F.V.C., unpublished data). The current results provide a compelling rationale for examining the role of RNA-containing exosomes in the delivery of these evolutionarily and structurally distinct viral RNAs to pDCs.
EXPERIMENTAL PROCEDURES

Biological Materials
Unless otherwise indicated, a subclone of Huh-7.5.1 cells (Huh-7.5.1c2; Dreux et al., 2009; Gastaminza et al., 2010; Pedersen et al., 2007) that were infected by the JFH-1 infectious molecular clone of HCV and Huh-7.5.1c2 cells that harbor the JFH-1 SGR (Kato et al., 2003) were used in this study. In selected experiments, results were confirmed using Huh-7.5.1 cells from which the Huh-7.5.1c2 cells were derived (Figures S1, S4, and S5) , and the parental Huh-7 cell line. All cells were maintained in Dulbecco's modified Eagle's medium (Cellgro; Mediatech, Herndon, VA) supplemented with 10% fetal bovine serum (Cellgro), 10 mM HEPES, 100 units/ml penicillin, 100 mg/ml streptomycin, and 2 mM L-glutamine (Invitrogen, Carlsbad, CA) in 5% CO 2 at 37 C. Viral stocks of cell-culture adapted JFH-1 virus (D183; Zhong et al., 2006) were prepared by infection of Huh-7.5.1c2 cells at a multiplicity of infection (moi) of 0.01, as described previously (Dreux et al., 2009) . pDCs were isolated from 450 ml of blood from healthy adult human volunteers after informed consent was obtained according to procedures approved by the Scripps Research Institute Human Research Committee. Briefly, PBMCs were isolated using Ficoll-Hypaque density centrifugation, and pDCs were positively selected from PBMCs using BDCA-4-magnetic beads (MACS Miltenyi Biotec, Auburn, CA) according to the manufacturer's instructions. The typical yields of PBMCs and pDCs were 500 3 10 6 and 2 3 10 6 cells, respectively, with a typical purity of >95% pDCs. Isolated pDCs were maintained in RPMI 1640 medium (Cellgro) supplemented with 10% fetal bovine serum, 10 mM HEPES, 100 units/ml penicillin, 100 mg/ml streptomycin, 2 mM L-glutamine, nonessential amino acids, and 1 mM sodium pyruvate at 37 C/5% CO 2 . Detailed descriptions of the reagents and constructs are provided in Supplemental Experimental Procedures.
Detection of HCV RNA in pDC/HCV-SGR Cell Cocultures by FISH Analysis
After isolation, pDCs were cocultured with HCV-SGR cells for 20 hr at 37 C. After 4% paraformaldehyde fixation at room temperature and washing with phosphate-buffered saline, HCV plus strand RNA was detected using a probe set that targets a region between nucleotide positions 2733 and 4870 in the JFH-1 genome (Panomics/Affymetrix, Santa Clara, CA) according to the manufacturer's instructions. For immunostaining, mouse anti-IFN-a (MACS Miltenyi Biotec, Auburn, CA) was diluted at 2 mg/ml using blocking and binding buffers as previously described (Dreux et al., 2009) Figure 6 . ESCRT Proteins Are Required for Production of the pDC-Activating Signal by HCV-SGR and HCV-Infected Cells (A and B) The impact of shRNA-mediated CHMP4B downregulation, using two different shRNAs (#30 and #69, described in Table S1 ) (A) and shRNA-mediated TSG101 downregulation (B) on expression of the corresponding proteins (upper panels), levels of IFN-a in HCV-SGR Huh-7.5.1c2 cell-pDC coculture supernatants (middle panels), and intracellular HCV RNA in Huh-7.5.1c2 SGR cells (lower panels) was compared with HCV-SGR cells transduced with shRNA against Analysis of Extra-and Intracellular RNA Levels Supernatants of 80% confluent HCV-SGR cells were cleared by 2,000 3 g centrifugation for 20 min at 4 C followed by filtration through a 0.22 mm filter (Corning). Precleared supernatants were treated with 0.5% NP40, 100 mg/ml RNase, and/or 0.4 U/ml RNase inhibitors for 1 hr at room temperature with agitation. The efficiency of RNA extraction and quantitative RT-PCR (qRT-PCR) was controlled by adding in vitro transcribed Xef1a (Xenopus transcription factor 1a) to supernatants diluted in guanidinium thiocyanate citrate buffer (GTC). Extracellular HCV-RNA, Xef1a, and GAPDH mRNA levels were determined by qRT-PCR as previously described (Dreux et al., 2009) . Extraand intracellular HCV-RNA levels were normalized for Xef1a and GAPDH GFP and an shRNA against an unrelated cellular protein (Atg4B) or nontransduced HCV-SGR cells (À). HCV-negative Huh-7.5.1c2 cells served as controls (cont cells). The hatch marks (#) indicate results below the limit of detection of the IFN-a ELISA (12.5 pg/ml). Results are representative of two independent experiments, each performed in triplicate. Error bars represent the mean ± SD. NS, nonspecific band; PR, Ponceau red staining; MW, molecular weight marker.
(C-E) CHMP4B and TSG101 downregulated Huh7.5.1c2 cells, infected by HCV (moi of 5 for 48 hr) were cocultured with pDCs for 20 hr. The levels of CHMP4B and TSG101 expression (C), IFN-a in coculture supernatants (D, upper panel), intracellular HCV RNA (D, lower panel), and titration of HCV infectious particles in supernatants of the infected cells (E) were compared with control HCV-infected cells transduced with shRNA against GFP. Uninfected Huh-7.5.1c2 cells served as controls (cont cells). Results are representative of two independent experiments, each performed in triplicate. Error bars represent the mean ± SD. See also Figure S3 . Figure 7 . ANXA2 Is Required for HCV-Infected and SGR Cells to Trigger IFN-a Production by pDCs (A-C) shRNA-mediated downregulation of ANXA2 protein in HCV-SGR Huh-7.5.1c2 cells (A) strongly reduced IFN-a production by cocultured pDCs (B), but had no impact on HCV replication (C). All results were compared with ANXA2 shRNAtransduced HCV-SGR Huh-7.5.1c2 cells that ectopically express an shRNA-resistant variant of ANXA2 (Rescue). Results are representative of two independent experiments, each performed in triplicate. NS, nonspecific band; MW, molecular weight markers. (D-G) Levels of downregulation of ANXA2 expression in HCV-infected Huh-7.5.1c2 cells (moi of 5 for 48 hr) (D), IFN-a in HCV-infected cell-pDC coculture supernatants (E), intracellular HCV RNA in HCV-infected cells (F), and HCV infectious particles in supernatants of the infected cells (G) were compared with HCV-infected cells transduced with an shRNA against GFP. HCV-negative Huh-7.5.1c2 cells served as controls (cont cells). The hatch marks (#) indicate results below the limit of detection of the IFN-a ELISA (12.5 pg/ml). Error bars represent the mean ± SD. See also Figure S4 .
RNA levels, respectively. The sequences of the primers are described in Table S1 . A detailed description of the procedure used for northern blot analysis is provided in Supplemental Experimental Procedures.
Exosome Isolation
Supernatants were precleared by sequential lowand high-speed centrifugation as follows: Briefly, supernatants of 80% confluent HCV-SGR cells were harvested twice (2 hr apart) and clarified by centrifugation at 2,000 3 g for 20 min (4 C), yielding supernatants that were further clarified by centrifugation at 10,000 3 g for 30 min (4 C). Exosomes in the clarified supernatants were then pelleted at 110,000 3 g for 2 hr at 4 C using a SW28 rotor, as previously described (Thé ry et al., 2006) . The pelleted exosome preparations were resuspended in exosome-depleted medium. Approximately 0.25-0.5 mg of exosomal proteins were usually obtained from 1-2 3 10 6 cells. For each exosome isolation, the purity of the preparation was determined by western blot analysis, as described in Supplemental Experimental Procedures.
Downregulation by Lentivirus Vector-Based shRNA Transduction and Expression Rescue Assay
Lentivirus vector-based shRNA was produced as described previously (Dreux et al., 2009) 
and details are provided in Supplemental Experimental
Procedures. The sequences of the shRNA are provided in Table S1 . ANXA2 expression was rescued by transduction of ANAX2 downregulated cells with a murine leukemia virus-based vector that permits expression of an ANXA2-shRNA resistant cDNA. Details are provided in Supplemental Experimental Procedures.
Coculture Experiments
Unless otherwise indicated, 2 3 10 5 HCV-SGR cells, infected cells, or parental cells were cocultured with 2 3 10 4 pDCs in 96-well round-bottom plates in a 37 C/5% CO2 incubator. Twenty hours later, cell-culture supernatants were collected and IFN-a levels were measured with the use of a commercially available ELISA kit (PBL Interferon Source, Piscataway, NJ) according to the manufacturer's instructions.
SUPPLEMENTAL INFORMATION
Supplemental Information includes four figures, one table, and Supplemental
Experimental Procedures and can be found with this article online at http://dx. doi.org/10.1016/j.chom.2012.08.010.
